Dr. Nancy E. Backus, MD
Internal Medicine (Internal Medicine Physician)
Medicare and federal program status
Opted out of Medicare from July 1, 2022 through July 1, 2028. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated August 14, 2026). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- Medical school
- Mercer University School of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2008
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2012Medical school: Mercer University School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
GA license 73206
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Candler Hospital Savannah, GA
- St Joseph's Hospital - Savannah Savannah, GA
- Savannah Health Services LLC DBA Memorial Health University Medical Center Savannah, GA
Medical groups
- Effingham Rehab Services, LLC (155 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in Savannah, GA | 97 |
| Nifedipine Er (nifedipine) Other prescribers in Savannah, GA | 52 |
| Trazodone Hcl Other prescribers in Savannah, GA | 49 |
| Levothyroxine Sodium Other prescribers in Savannah, GA | 47 |
| Pantoprazole Sodium Other prescribers in Savannah, GA | 46 |
| Amlodipine Besylate Other prescribers in Savannah, GA | 40 |
| Duloxetine Hcl Other prescribers in Savannah, GA | 40 |
| Gabapentin Other prescribers in Savannah, GA | 39 |
| Mounjaro (tirzepatide) Other prescribers in Savannah, GA | 37 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Savannah, GA | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $15.85 in total to this clinician.
| Braeburn Inc. | $15.85 |
|---|
| Food and Beverage | $15.85 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $468,588 in research payments for these studies, mostly to the institutions running them.
- A phase 2B multicenter randomized doubleblind placebocontrolled study to evaluate the efficacy and safety of onceweekly MET097 in adults with obesity or overweight and type 2 diabetes mellitus VESPER2
Pfizer Inc. - A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants with Opioid Use Disorder
Merck Sharp & Dohme LLC - Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles
Mylan Inc. · Completed · NCT05139121 - Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Alnylam Pharmaceuticals Inc. - STUDY NAME# Cognition Platform Study
Merck Sharp & Dohme LLC - A Clinical Study to Evaluate a Cognitive Platform to Support Development of Symptomatic Therapies in Participants at Risk for Alzheimer s Disease
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.